...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacopsychiatry >Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia
【24h】

Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia

机译：急性和长期的Memantine对Risperidone的加入治疗改善了急性和慢性精神分裂症患者的认知功能障碍

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Patients with schizophrenia are mainly characterized by negative symptoms and cognitive dysfunction. In this proof-of-concept study we tested effects on cognition and negative symptoms of a 6- or 24-week memantine add-on treatment to risperidone in patients with acute or chronic schizophrenia. Materials and Methods Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo. All patients received antipsychotic medication with risperidone (2-8 mg/day). Psychopathological changes were assessed with the Positive and Negative Syndrome Scale (PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function was measured at baseline, after 6 weeks, and 24 weeks. Results Patients with acute schizophrenia who received add-on treatment with memantine showed a significantly higher performance in attention intensity (p=0.043), problem-solving (p=0.043), verbal learning (p=0.050), and flexibility (p=0.049). Patients with chronic schizophrenia showed a significantly higher immediate memory in the memantine group compared to the placebo group (p=0.033) and a significantly greater reduction of the PANSS sum score if compared to the placebo group. Discussions Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia. ClinicalTrials.gov Number: NCT00148590 and NCT00148616.
机译：引言精神分裂症患者主要是阴性症状和认知功能障碍的特征。在这种概念证明研究中，我们测试了对急性或慢性精神分裂症患者的Risperidone的6-4周或24周的记忆和阴性症状的对认知和阴性症状的影响。材料和方法患有精神分裂症（n = 11）的急性发作，占阳性症状的急性发作患者随机化为6周的含有Memantine（每天10毫克）与安慰剂和慢性精神分裂症患者（n = 13 ）和阴性症状随机与Memantine（每天两次）与Memantine（10毫克）随机化。所有患者均接受抗抗精神病药的药物药物（2-8毫克/天）。在基线和2,4,6,12和24周后，评估精神病理学变化和阴性综合征秤（平底锅）。在6周后，在基线和24周后测量认知功能。结果急性精神分裂症的患者接受致内的急性精神分裂症患者的关注强度表现出显着更高的性能（P = 0.043），问题解决（P = 0.043），口头学习（P = 0.050），灵活性（P = 0.049 ）。慢性精神分裂症患者显示出美金刚组中显著较高即时记忆比安慰剂组（p = 0.033），并且如果相对于安慰剂组的PANSS和得分的一个显著更大的减少。讨论我们的研究提供了进一步的证据表明，美金刚添加治疗利培酮可能具有保护作用，提高精神分裂症患者的认知功能。 ClinicalTrials.gov编号：NCT00148590和NCT00148616。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号